InnoTherapy Inc Cash Flow Conversion Efficiency
InnoTherapy Inc cash flow conversion efficiency. Based on the latest financial reports, InnoTherapy Inc (246960) has a cash flow conversion efficiency ratio of -0.004x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-107.41 Million ≈ $-72.79K USD) by net assets (₩24.57 Billion ≈ $16.65 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of InnoTherapy Inc (2015–2024)
Cash flow conversion efficiency of InnoTherapy Inc from 2015 to 2024. This chart illustrates how InnoTherapy Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View InnoTherapy Inc (246960) share price today for real-time trading data and today's change.
InnoTherapy Inc Cash Flow Conversion Ratio Explained
InnoTherapy Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
InnoTherapy Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of InnoTherapy Inc ranked by their cash flow conversion efficiency. Also see market value of InnoTherapy Inc for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Femasys Inc
NASDAQ:FEMY
|
-0.976x |
|
Ten-League International Holdings Limited Ordinary Shares
NASDAQ:TLIH
|
N/A |
|
Rugby Mining Limited
V:RUG
|
1.162x |
|
Tempest Security AB
ST:TSEC
|
0.232x |
|
Althea Group Holdings Ltd
AU:AGH
|
9.371x |
|
PNC Technologies co. Ltd
KQ:237750
|
0.017x |
|
Field Solutions Holdings Ltd
AU:FSG
|
0.158x |
|
Metacon AB
ST:META
|
-0.611x |
Annual Cash Flow Conversion Efficiency for InnoTherapy Inc (2015–2024)
The table below shows the annual cash flow conversion efficiency of InnoTherapy Inc from 2015 to 2024. Review 246960 FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩15.52 Billion ≈ $10.52 Million |
₩-5.96 Billion ≈ $-4.04 Million |
-0.384x | -157.47% |
| 2023-12-31 | ₩18.90 Billion ≈ $12.81 Million |
₩-2.82 Billion ≈ $-1.91 Million |
-0.149x | +52.60% |
| 2022-12-31 | ₩13.05 Billion ≈ $8.84 Million |
₩-4.10 Billion ≈ $-2.78 Million |
-0.315x | +20.39% |
| 2021-12-31 | ₩10.08 Billion ≈ $6.83 Million |
₩-3.98 Billion ≈ $-2.70 Million |
-0.395x | -78.14% |
| 2020-12-31 | ₩12.94 Billion ≈ $8.77 Million |
₩-2.87 Billion ≈ $-1.95 Million |
-0.222x | -2.53% |
| 2019-12-31 | ₩15.08 Billion ≈ $10.22 Million |
₩-3.26 Billion ≈ $-2.21 Million |
-0.216x | +5.49% |
| 2018-12-31 | ₩9.52 Billion ≈ $6.45 Million |
₩-2.18 Billion ≈ $-1.48 Million |
-0.229x | +68.62% |
| 2017-12-31 | ₩3.10 Billion ≈ $2.10 Million |
₩-2.26 Billion ≈ $-1.53 Million |
-0.730x | -294.88% |
| 2016-12-31 | ₩6.07 Billion ≈ $4.12 Million |
₩-1.12 Billion ≈ $-760.70K |
-0.185x | -200.06% |
| 2015-12-31 | ₩-6.23 Billion ≈ $-4.22 Million |
₩-1.15 Billion ≈ $-779.63K |
0.185x | -- |
About InnoTherapy Inc
SCL Science Inc. produces medical hemostatic agents using biomimetic technology. Its products include BiMM (Bio-inspired Medical Materials) that reacts immediately with blood; Endoseal, which is used for specialized indication of gastrointestinal bleeding; InnoSeal, a hemostatic agent that is used in various surgical fields, such as cardiology, radiology, and neurosurgery; Jelly Seal, a hemostasi… Read more